Fundraising Fox
/Companies
Sign in

Antag Therapeutics

Copenhagen, DK · Founded 2017 · 23 employees on LinkedIn · 10 known investors

Find your way into Antag Therapeutics

Each arrow is one introduction. Sign up to fill in the first one.

209 people can intro you to Mette

Ask Iqbal Mufti to introduce you to Mette Rosenkilde

You →Iqbal · together at Antag Therapeutics →Mette

Sign up to find every way you can get introduced to Antag Therapeutics

  • Your email: who you already know at Antag Therapeutics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Antag Therapeutics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Antag Therapeutics develops GIP receptor antagonist therapies for obesity, diabetes, and overweight patients. The company's lead candidate, AT-7687, is a clinical-stage peptide designed to block dysfunctional biological pathways contributing to fat storage and metabolic dysfunction, offering an alternative treatment approach with improved tolerability.

BiotechHealthtech

Founders & leadership

Antag Therapeutics was founded in 2017 by Jens Juul Holst and Mette Rosenkilde.

JJJens Juul Holst
Jens Juul HolstFounder
MRMette Rosenkilde
Mette RosenkildeFounderMette Rosenkilde is a pharmacologist and researcher at Copenhagen University focused on G protein-coupled receptor biology and metabolic diseases; she founded Antag Therapeutics based on years of collaborative research at the university to develop novel treatments for dietary-related metabolic disorders.

Investors · 10

Novo Holdingslisted by Novo HoldingsCopenhagen · $1.1M – $54M

How we know: Novo Holdings's portfolio page · funding news · prnewswire.com · open dataset · 5k.vc investor directory · Not right? Tell us

SR One Capital Managementlisted by SR One Capital ManagementRedwood City

How we know: SR One Capital Management's portfolio page · Not right? Tell us

Versant VenturesreportedSan Francisco · $250K – $5M

How we know: a partner's Signal profile · funding news · prnewswire.com · Not right? Tell us

Also in the syndicate · 6

Dawn BiopharmaExport and Investment Fund of DenmarkExport and Investment Fund of Denmark (EIFO)Longview VenturesPictetSR One

Funding

SEC filings, press & company announcements
  • Undisclosed amountSeries ADec 2024 · 2 sources

    Versant Ventures (lead), Dawn Biopharma, Export and Investment Fund of Denmark, Export and Investment Fund of Denmark (EIFO), Longview Ventures, Novo Holdings, Pictet, SR One

    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Founder mafia

2 people who came through Antag Therapeutics went on to found or lead other companies.

Mads Emil MatthiesenCo-FounderFounded CathVisionJayson DallasDirector Board of DirectorsFounded Aimmune Therapeutics

In the news

Antag Therapeutics appoints obesity treatment pioneer Philip Just Larsen as Chief Executive Officerglobenewswire.com · May 2026Antag Therapeutics Announces €80 Million Series A Financingprnewswire.com · Dec 2024

Frequently asked questions

What does Antag Therapeutics do?
Antag Therapeutics develops GIP receptor antagonist therapies for obesity, diabetes, and overweight patients. The company's lead candidate, AT-7687, is a clinical-stage peptide designed to block dysfunctional biological pathways contributing to fat storage and metabolic dysfunction, offering an alternative treatment approach with improved tolerability.
Who founded Antag Therapeutics?
Antag Therapeutics was founded by Jens Juul Holst, Mette Rosenkilde in 2017.
Who are Antag Therapeutics's investors?
Antag Therapeutics's investors include Broadview Ventures, Novo Holdings, SR One Capital Management, Versant Ventures.
Where is Antag Therapeutics headquartered?
Antag Therapeutics is headquartered in Copenhagen, DK.